Dustin Devers, DO
Family Medicine · Paintsville, KYNPI 1699989640
Payments from drug & device makers
Across 240 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$760
- AstraZeneca$425
- GSK$353
- Lilly USA, LLC$250
- Johnson & Johnson$168
- Otsuka America Pharmaceutical, Inc.$159
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,12798%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $760 |
| AstraZeneca | 19 | $425 |
| GSK | 19 | $353 |
| Lilly USA, LLC | 15 | $250 |
| Johnson & Johnson | 9 | $168 |
| Otsuka America Pharmaceutical, Inc. | 7 | $159 |
| Pfizer | 10 | $156 |
| Teva Pharmaceuticals USA, Inc. | 8 | $147 |
| CSL Behring | 6 | $144 |
| Jazz Pharmaceuticals Inc. | 6 | $140 |
| Abbott | 6 | $126 |
| Medtronic(2 entities) | 4 | $110 |
| Ironshore Pharmaceuticals Inc. | 6 | $110 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Novartis | 6 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Novo Nordisk | 4 | $80 |
| Amgen | 5 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $59 |
| Lundbeck LLC | 3 | $53 |
| Insulet Corporation | 3 | $51 |
| Exact Sciences | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $36 |
| Corium, LLC | 3 | $34 |
| Dexcom, Inc. | 2 | $31 |
| Bayer | 2 | $29 |
| Almatica Pharma LLC | 1 | $27 |
| Melinta Therapeutics, LLC | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| CMP Pharma, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,192 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 400 | $152,114 |
| OzempicSemaglutide | 66 | $105,449 |
| TrulicityDulaglutide | 49 | $67,716 |
| MounjaroTirzepatide | 48 | $56,674 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $49,893 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $48,931 |
| AustedoDeutetrabenazine | 28 | $43,610 |
| Risperdal ConstaRisperidone Microspheres | 36 | $35,689 |
| XareltoRivaroxaban | 69 | $33,473 |
| LinzessLinaclotide | 49 | $32,867 |
| Pirfenidone | 12 | $31,973 |
| EntrestoSacubitril/Valsartan | 73 | $31,420 |
| MyrbetriqMirabegron | 35 | $30,585 |
| JanuviaSitagliptin Phosphate | 24 | $24,456 |
| VraylarCariprazine Hcl | 36 | $24,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $156 | $157,452417 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $250 | $124,39097 claims |
| Novo NordiskOzempic | $80 | $105,44966 claims |
| Johnson & JohnsonRisperdal Consta, Xarelto | $168 | $69,162105 claims |
| AbbVieLinzess, Vraylar | $760 | $56,95985 claims |
| GSKTrelegy Ellipta | $353 | $49,89367 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $147 | $43,61028 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $425 | $38,08269 claims |
| NovartisEntresto | $100 | $31,42073 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $30,58535 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $40 | $13,56758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Paintsville
- Jason RicePaintsville$12K
- Brandi CollinsPaintsville$12K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.